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Introduction
Tumor suppressors play a pivotal role in controlling unsched-
uled cell proliferation and they act as gatekeepers that block 
neoplastic progression. The expression of tumor suppressors is 
downregulated in tumor cells by means of genetic and epigenetic 
mechanisms, while recent evidence points to their regulation also 
by microRNAs.1-3 Epigenetic silencing modifications, such as 
DNA and histone methylation, impact chromatin structure and 
restrict the physical access of the nuclear factors to the underlying 
DNA. At the promoter level, this epigenetic state results in 
inhibition of tumor suppressor gene transcription.2,4,5 Reversal 
and modification of the tumor suppressor epigenetic state can 
be achieved by blocking DNA and histone methyltransferases 
as well as histone deacetylases.6,7 While drugs can be used to 
achieve the inhibition of these enzymes in an untargeted manner, 
the precise mechanisms and the genetic cascades whereby these 
drugs induce biological changes are currently not well under-
stood. Moreover, given that tumor suppressors sustain anti-pro-
liferative and anti-metastatic functions, it is essential to target 
the native tumor suppressor function in order to develop more 
effective therapies.
MASPIN, or SERPINB5, is a class II tumor suppressor gene 
that is not found mutated or rearranged in tumor cells, but is 
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silenced during neoplastic progression.8 MASPIN silencing 
involves transcriptional regulation [via p53,9 ETS,10 AP-110 and 
hormone receptor11 (HR) transcription factor], aberrant pro-
moter methylation12,13 and microRNAs (miR-213). High levels 
of MASPIN are associated with reduction of tumor growth,14 
decreased angiogenesis,15 cell motility and invasion,16,17 as well as 
metastatic dissemination.18-21 The clinical relevance of MASPIN 
has been demonstrated in several types of human cancers 
including breast,22,23 prostate,24 colon,25 lung26 and melanoma27 
malignancies.
Lung cancer is associated with high mortality and poor 
patient survival, mainly due to the lack of effective therapies. 
NSCLC, which are characterized by slow tumor cell growth and 
dissemination, are particularly refractory to chemotherapy and 
chest radiotherapy. In these carcinomas, MASPIN expression is 
a prognosis marker hence tumor specimens that are MASPIN 
positive are associated with better patient survival than tumor 
samples that lack MASPIN expression.26,28,29 However, little is 
known about the precise mechanism and biological function of 
MASPIN in NSCLC. MASPIN silencing is correlated with lung 
cancer progression, metastasis and invasiveness.30 Silencing of 
MASPIN in highly aggressive NSCLC has been associated with 
epigenetic regulation in which DNA methylation appears to be 
a key mechanism for silencing.31 Since methylation is a reversible 
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Overall, these experiments indicate that ATFs are able to epige-
netically reprogram aggressive lung tumor cells towards a more 
epithelial, differentiated phenotype and, thus, represent novel 
therapeutic agents for metastatic lung cancers.
Results
MASPIN expression in nsclc cell lines. We first performed 
quantitative real-time PCR (qRT-PCR) to evaluate MASPIN 
mRNA levels. As shown in figure 1a, these experiments revealed 
two categories of NSCLC cell lines, those with high- and low-
MASPIN expressing cells. Interestingly, no significant differences 
in MASPIN expression were observed between the non-trans-
formed immortalized lung epithelial cell line BEAS-2B, which 
expresses MASPIN, and the high-MASPIN expressing cells. 
In contrast, significant differences in MASPIN expression levels 
were detected between the high- and low-MASPIN expressing cell 
lines. The MASPIN mRNA levels in the high- and low-MASPIN 
expressing cell lines correlated with the amount of MASPIN pro-
tein as shown by western blot (fig. 1B).
Silencing of MASPIN in cancer cell lines has been previously 
associated with increased cellular invasiveness.17,40 We subse-
quently investigated the in vitro invasion ability in a panel of 
NSCLC cells by performing Matrigel invasion assays. As shown 
in figure 1c, a reverse correlation between MASPIN expression 
and invasion ability was observed, corroborating previously pub-
lished findings in breast and lung cancer lines.16,17,30,33 Overall 
our results show that high-MASPIN expressing cells were sig-
nificantly less invasive than low-MASPIN expressing cells.
Next, we analyzed MASPIN protein expression and cellular 
localization in the NSCLC cell lines by immunofluorescence. As 
shown in figure 1d, the immortalized lung epithelial cell line 
(BEAS-2B) and the cancer cell line NCI-460 localized MASPIN 
both in the nucleus and in the cytoplasm, whereas that in other 
NSCLC cell lines, such as NCI-H2009 and NCI-H2122, 
MASPIN was expressed mainly in the cytoplasm. As expected, 
we did not detect any MASPIN protein by immunofluorescence 
in the Low-MASPIN expressing cell line panel (including the 
NCI-H157 cell line). Overall these results suggest that MASPIN 
is silenced in a group of NSCLC and as expected, loss of MASPIN 
expression correlated with invasion ability.30
atfs reactivate MASPIN in nsclc cell lines. Previously, 
we have described the construction of three ATFs designed to 
bind 18-bp sites on the MASPIN proximal promoter.28 The ATFs 
were constructed by linking six sequence-specific ZF domains 
with the VP64 activator domain. Among all ATFs, only ATF-
126 was able to reactivate MASPIN in breast cancer cell lines.33 
In this study, we investigated if the same ATFs were able to reac-
tivate MASPIN in the NSCLC cell panel (fig. 1). The ATFs 
were delivered into NSCLC cell lines using the retroviral vec-
tor PMX-IRES-GFP, which allowed the tracking of transduced 
cells by flow cytometry using the GFP as a marker.38 Seventy-
two hours post-transduction cells were collected and processed 
for qRT-PCR analysis. First, we transduced two high-MASPIN 
expressing cell lines, NCI-H358 and NCI-H460. As shown in 
figure 2a, two ATFs (ATF-97 and ATF-126) targeting the 
event, efforts have been made to restore MASPIN expression in 
cancer cells thereby inducing its tumor and metastasis suppressive 
functions.32,33 Ectopic expression of MASPIN-encoded cDNA 
or reactivation of endogenous MASPIN in breast cancer cells 
perturb multiple cellular networks, such as apoptosis and motil-
ity.33-35 Furthermore, ectopic expression of MASPIN in tumor 
cells results in reprogramming of the tumor cell proteosome, 
which affect multiple processes during tumor progression.36,37
In previous work we have described a strategy that combines 
chromatin-remodeling drugs and ATFs to overcome the epigen-
etic repression of MASPIN in breast cancer cells.33 ATFs com-
posed of modular zinc finger (ZF) domains were designed to bind 
unique 18-base pair (bp) sites in the MASPIN proximal promoter. 
The ATFs were constructed by linkage of six sequence-specific 
zinc finger domains with the VP64 transactivator domain, which 
is a tetramer of the herpex simplex virus VP16 activator domain.38 
Each ZF is a compact 30-amino acid domain composed of a rec-
ognition a-helix packed with two antiparallel b-strands coordi-
nated with a zinc ion. The a-helix of each zinc finger specifically 
recognizes three bp in the DNA. Three MASPIN specific ATFs 
were engineered with recognition a-helices specific for their cor-
responding target sites in the MASPIN promoter using previously 
characterized ZF domains.33
Among the three designed ATFs, ATF-126 was able to par-
tially reactivate MASPIN in several breast cancer cell lines car-
rying a methylated MASPIN promoter.33,39 Interestingly, the 
degree of MASPIN reactivation by ATFs appeared to be cell line 
dependent. This suggests that the structure of the chromatin 
in the target promoter influences the regulatory potential of 
ATFs. Moreover, little is known as to how ATFs crosstalk with 
their chromatin microenvironments. Most importantly, it is 
presently unknown if ATFs are indeed able to modify indi-
vidual epigenetic marks such as DNA methylation. To address 
these questions, we took advantage of the MASPIN specific 
ATFs to investigate if they could influence hypermethylated 
promoter microenvironments in highly aggressive NSCLC cell 
lines. Since NSCLC are known to silence MASPIN by DNA 
methylation,31 we hypothesized that our ATFs could reacti-
vate MASPIN by modifying the methylation status of the pro-
moter. This should result in specific reactivation of MASPIN 
tumor suppressive functions as well as inhibition of metastatic 
behavior, which is a hallmark of NSCLC. Such reactivation of 
MASPIN may provide a powerful therapeutic tool for NSCLC 
as well as novel insights on how MASPIN mediates its functions 
in metastatic lung cancers.
In this paper, we have examined the effect of ATFs in com-
bination with chromatin modifiers to upregulate MASPIN in a 
panel of NSCLC cell lines. We found that reactivation of the 
endogenous MASPIN in low-MASPIN expressing cells treated 
with a combination of ATFs and chromatin modifiers induced 
apoptosis and suppressed metastasis in immunodeficient mice. 
Furthermore, restoration of endogenous MASPIN expression 
also resulted in upregulation of E-CADHERIN thereby induc-
ing a more differentiated epithelial phenotype in lung cancer 
cells. In addition, we show that ATFs linked to transactivator 
domains resulted in the demethylation of the MASPIN promoter. 
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Figure 1. MASPIN expression in a panel of NscLc cell lines. (a) MASPIN mRNa expression levels by 
quantitative real-time pcR in a panel of NscLc cell lines. MASPIN mRNa levels were normalized to the 
immortalized bronchial epithelial cell line (BEas-2B). Data represent the mean ± sD of three independent 
experiments. (B) MaspIN protein expression in high- and low-MASPIN expressing cell lines. (c) Loss of 
MASPIN expression correlates with invasion abilities in NscLc cell lines. (D) Immunofluorescence staining 
of MaspIN in BEas-2B and in the NscLc cell lines. ↑ Indicates nuclear and ➭ indicates cytoplasmic 
staining, respectively.
MASPIN proximal promoter (posi-
tions-97 and -126 upstream of the 
translation start site, respectively) 
were able to upregulate MASPIN in 
both cell lines as compared to con-
trol (cells transduced with an empty 
retroviral vector). In these cell lines 
the ATFs-97 and -126 upregulated 
MASPIN by 1.5- and 2-fold rela-
tive to controls. As illustrated in 
figure 2B, both ATFs, ATF-97 
and -126, were able to upregulate 
MASPIN by 25- to 125-fold rela-
tive to controls in lung cells hav-
ing a silenced MASPIN promoter. 
Similarly to what we reported in 
breast cancer lines,33,39 ATF-452 had 
no significant activity in NSCLC 
lines. Effective ATF expression was 
also verified by qRT-PCR, using 
ATFs-specific primers (sup. fig. 1). 
Subsequently we focused on the 
NCI-H157 cell line as an archetype 
of an aggressive, low-MASPIN line, 
to study the functional and pheno-
typic properties of MASPIN reacti-
vation by ATFs.
atf-97 and atf-126 induced 
apoptosis and suppressed cell 
invasion in nci-h157 cells. We 
first examined if expression of 
the ATFs induced the apoptotic 
function of MASPIN in NCI-
H157 cells. We quantified the 
fraction of early apoptotic cells 
by Annexin V staining 96 h post-
transduction. Non-transduced 
and transduced cells were stained 
and analyzed by flow cytom-
etry. As illustrated in figure 3a, 
ATF-97 and ATF-126 were able to 
induce apoptosis in NCI-H157 cells 
(44 and 45%, respectively) relative 
to control cells (cells transduced 
with an empty retroviral vector). 
As expected, ATF-452, which had 
no impact on MASPIN expression, 
had no significant effect in induc-
ing apoptosis. These results dif-
fer from the breast cancer cell line 
models, in which only ATF-126 was able to induce apoptosis.39 
In lung cancer cell line models both ATFs induced MASPIN 
re-expression at similar levels, suggesting that cell type specific 
chromatin structure strongly influences the potential of ATFs 
to transactivate target promoters.
Next, we examined the capability of the ATFs to decrease the 
invasion ability of the highly invasive NCI-H157 cell line. For 
this purpose, we performed matrigel invasion assays with non-
transduced cells as well as cells transduced with ATFs and con-
trols. As we expected from their capability to regulate MASPIN 
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ATF-97 and ATF-126 generated fewer number of colonies as 
compared to controls. Furthermore, control colonies exhib-
ited a scattered amorphous shape with a complete loss of 
polarity, indicative of invasive properties. In contrast, both 
ATF-97- and ATF-126-transduced colonies appeared to 
have round and compact structure, suggesting the acquisi-
tion of epithelial-like properties. These results suggested that 
ATF-97 and ATF-126 were able to induce a more epithelial 
and less invasive phenotype in the highly aggressive NCI-
H157 cell line.
To further examine the effects of ATF-97 and ATF-126 
on cell polarity, we performed a three-dimensional matrigel 
culture assay. As shown in figure 3d, ATF-97 and ATF-126 
had a dramatic effect on the morphologic architecture of the 
NCI-H157 cells cultured in a three-dimensional matrix. 
Non-transduced cells and controls formed a disorganized 
aggregation of cells whereas that ATF-97 and ATF-126 gen-
erated highly organized spheroid structures (fig. 3d). These 
data suggest that MASPIN re-expression in NCI-H157 cells 
induced the acquisition of a more differentiated epithelial 
phenotype. To further explore this phenotype, we investi-
gated the expression of E-CADHERIN, which plays a criti-
cal role for maintenance of normal epithelial function and 
architecture of epithelial cells. We analyzed E-CADHERIN 
mRNA levels in non-transduced, transduced and control 
NCI-H157 cells. We observed that in ATF-transduced cells 
E-CADHERIN mRNA levels were upregulated 50-fold rela-
tive to controls (fig. 3e) at 72 h post-transduction. These 
results suggested that MASPIN re-expression could regu-
late in vitro growth and invasive abilities of NCI-H157 cells 
including re-expression of E-CADHERIN and the acquisi-
tion of a more differentiated epithelial phenotype. Overall 
these results demonstrate that re-activation of endogenous 
MASPIN by ATFs resulted in suppression of tumor cell 
growth and invasion in NSCLC cell lines.
atf-126 abolishes experimental metastasis develop-
ment in animal models. The results described above dem-
onstrated that both, ATF-97 and ATF-126 induced similar 
phenotypes in knocking-down cell invasion in vitro. We 
next focused on ATF-126 to study the ability of this ATF 
to decrease lung metastasis formation in a mouse model 
using non-invasive, bioluminescence imaging (BLI). The 
injection of cancer cells into the left cardiac ventricle of 
immunodeficient mice has been extensively used as animal 
model of bone and brain metastasis.41 The NCI-H157-luc 
cells (stably expressing the firefly luciferase gene, Luc) were 
transduced with either a control (empty retroviral vector) or 
ATF-126-expressing retroviral vector (pMX-IRES-ATF-126-
GFP). Twenty-four hours post-transduction 1 x 105-transduced 
cells were injected into the left ventricle of SCID mice (N = 
5 per group). Animals were imaged 15 min after injection by 
monitoring luciferase activity. Four of the control animals and 
five of the ATF-126 animals exhibited a diffuse photon accu-
mulation over the entire body, suggesting effective injection. 
Upon intracardiac injection, one control animal showed signs of 
distress and died within an hour post-injection. The surviving 
expression, ATF-97 and ATF-126 were both able to downregu-
late cell invasion relative to controls (fig. 3B).
We subsequently investigated if the ATFs were able to suppress 
tumorigenicity in vitro. We performed an in vitro colony forma-
tion assay in soft agar, which measure anchorage-independent 
growth, and is considered the most stringent assay for detect-
ing malignant transformation of cells in vitro. ATF-transduced 
cells and controls were seeded in soft agar for 28 days. Following 
this incubation period, colonies were analyzed morphologically 
and quantified. As shown in figure 3c, cells transduced with 
Figure 2. aTFs regulate MASPIN in high- and low-MASPIN expressing NscLc 
cell lines. (a) Relative MASPIN mRNa upregulation in the high-MASPIN 
expressing cell lines NcI-h358 and NcI-h460. (B) Relative MASPIN expres-
sion in the low-MASPIN expressing cell lines NcI-a549, NcI-h157, NcI-h226, 
NcI-h520, NcI-h1703 and NcI-h661. MASPIN mRNa expression levels were 
measured by quantitative real-time pcR and data was normalized to the 
untransduced cell lines. Experiments were run in triplicate and data repre-
sent the mean ± sD of three independent biological replicates (*p < 0.05, 
as determined by aNOVa). cell line refers to untransduced NscLc cell lines; 
control, cells transduced with an empty retroviral vector; aTF-97, aTF-126 and 
aTF-452, cells transduced with the corresponding aTFs; aTF-126NOVp is a 
control aTF-126 lacking the Vp64 activator domain; pMXVp64-ss is a control 
vector expressing the Vp64 activator domain only.
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to abolish metastasis formation in the highly aggressive NCI-
H157 lung cell line.
atf-97 and atf-126 demethylate the MASPIN proximal 
promoter. As a class II tumor suppressor gene, the MASPIN gene 
has not been found mutated or deleted in cancer cells. In con-
trast, it is well known that MASPIN is regulated by epigenetic 
mechanisms.13 To investigate whether the MASPIN promoter 
was methylated at DNA level in NCH-H157 cells, we performed 
a sodium bisulfite sequencing of the MASPIN promoter after 
72 h post-transduction. As shown in figure 5a, the MASPIN 
promoter was found methylated with frequencies close to 100%. 
The ATF-97- and ATF-126-binding sites comprised one and 
animals were imaged every week for a total of 12 weeks. Among 
the three control animals, only two developed metastasis after 
three weeks post-injection. The BLI in these control animals 
revealed distinct areas of photon accumulation, indicative of 
metastatic tumor growth, over the ventral projection of the 
thoracic vertebrae, the maxillofacial region and dorsal projec-
tion of the spine (fig. 4). Control animals were euthanized at 
week six due to the large size of the metastatic lesions. These 
results illustrate the aggressive potential of the NCI-H157 lung 
cancer cell line. Noteworthy, the animals injected with ATF-
126-transduced cells did not develop metastasis during the 
12 weeks of imaging (fig. 4), suggesting that ATF-126 was able 
Figure 3. aTFs induce apoptosis and 
reduce cell invasion in the NcI-h157 
NscLc cell line. (a) aTF-97 and aTF-
126 induce apoptosis in NcI-h157 
cells. The percentage of apoptosis 
was quantitatively analyzed in 
untransduced cells, control cells and 
in aTF-transduced cells using an 
annexin-V staining. apoptosis was 
measured 96 h post-transduction. 
Data represents an average of three 
independent experiments  
(**p < 0.01, as determined by the 
student’s t-test). (B) aTFs downregu-
late cell invasion in NcI-h157 cells in 
matrigel invasion assays. Left panel 
shows a representative picture of 
invasive cells. Right panel shows the 
quantification of invasive cells. Ex-
periments were run in triplicate and 
data represents an average of three 
different biological replicates (**p < 
0.01, as determined by the student’s 
t-test). (c) In vitro colony formation 
assay in soft agar. The morphology 
of colonies of control and aTF-trans-
duced cells are indicated. (D) 3D 
Matrigel culture assay illustrating 
that aTF-97- and aTF-126-transduced 
cells form colonies with an organized 
spheroid structure. (E) Expression of 
E-CADHERIN by qRT-pcR in control 
and aTF-transduced cells. Data was 
normalized to the untransduced 
cell line. Experiments were run in 
triplicate and data represent the 
mean ± sD three independent 
experiments (**p < 0.01, as deter-
mined by student’s t-test). NcI-h157 
refers to untransduced cells; control, 
cells transduced with an empty 
retroviral vector; aTF-97, aTF-126 and 
aTF-452, cells transduced with the 
corresponding aTFs; aTF-126NOVp 
is a control aTF-126 lacking the Vp64 
activator domain.
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5-Aza-2'-dC resulted in a concomitant synergistic effect in induc-
ing apoptosis, as assessed by Annexin V staining (sup. fig. 2). 
The differences in the levels of MASPIN reactivation in response 
to the methyltransferase inhibitor in combination with the two 
different ATFs could be due to local differences in chromatin 
structure among the cell lines examined.
Discussion
In this work we have investigated the ability of ATFs to reactivate 
MASPIN expression and to reduce tumor growth and metastatic 
dissemination in NSCLC cell lines carrying a hypermethylated 
promoter. We found that the ATFs were able to demethylate the 
MASPIN promoter and reactivate the endogenous gene. This was 
associated with tumor- and metastasis-suppressive functions as 
well as a phenotypic reprogramming of the aggressive lung tumor 
cells towards a more differentiated, epithelial phenotype.
Lung cancers are particularly aggressive and associated with 
high mortality due to their ability to colonize and quickly metas-
tasize. Therefore, there is a clear need to develop novel targeting 
strategies for metastatic lung cancers. Extensive research in the 
field has revealed that high MASPIN expression is associated with 
improved prognosis and patient survival.26,28,29,42,43 In lung carci-
nomas the MASPIN gene is not mutated or deleted but is silenced 
by a variety of molecular mechanisms, including transcription 
factors (for example, p5344 and p6330) and epigenetic regula-
tion (DNA methylation31). Importantly, the level of MASPIN 
promoter methylation correlates with tumor’s aggressiveness.45 
Given that methylation is a reversible event, the specific restora-
tion of endogenous MASPIN expression represents a promising 
therapeutic strategy to block lung cancer progression.
In previous work we have described the generation of ATFs 
as novel molecular tools to restore the endogenous expression 
of MASPIN in tumor cells.33 We hypothesized that ATFs could 
provide a unique opportunity to specifically alter the epigenetic 
silencing of MASPIN in hyper-methylated promoter microenvi-
ronments.39 The results of this work show that ATFs designed 
to bind methylated DNA sequences in the MASPIN promoter 
are able to reactivate the endogenous gene in a panel of NSCLC 
cell lines. Importantly, the ATFs induced MASPIN expression 
in the NCH-H157 cell line, which contains a hypermethylated 
promoter with methylation frequencies close to 100%. The reac-
tivation of MASPIN appeared to be specific, since transduction of 
ATFs lacking the MASPIN-specific DNA-binding domains had 
no impact on MASPIN expression. Furthermore, truncated ver-
sions of ATF-126 and ATF-97 lacking the VP64 domain were 
not able to reactivate the gene.
It is presently unknown how the ATFs gain access to a 
hypermethylated MASPIN promoter. Both DNA- and histone 
methylation are epigenetic silencing marks associated with a 
compacted chromatin structure, which restricts the physical 
access of Transcription Factors and Pol II complex to the DNA.4 
Our results suggest that DNA-methylation represents indeed 
a partial blockade for gene reactivation, hence 5-Aza-2'-dC, a 
DNA-methyltransferase inhibitor, highly enhanced the transac-
tivation capabilities of the ATFs. Future experiments are required 
two CpG dinucleotides, respectively. However, neither the ATF-
452 nor the p53 binding sites contained CpG dinucleotides. 
To investigate if ATF-mediated upregulation of MASPIN resulted 
in changes in the MASPIN promoter methylation, we performed 
sodium bisulfate sequencing of ATF-97 and ATF-126 transduced 
NCI-H157 cells. As shown in figure 5c, the ATFs decreased the 
DNA methylation levels of the MASPIN promoter. Interestingly, 
the ATF-126 decreased the DNA methylation frequencies in the 
MASPIN promoter upstream the -126 binding site. In contrast, 
ATF-97 affected the DNA methylation frequencies in the pro-
moter region downstream the ATF-97 binding site.
atf-97 synergizes with 5-aza-2'-dc to reactivate MASPIN 
expression. To further investigate the influence of DNA meth-
ylation in the re-expression of MASPIN, we challenged ATF-
expressing cells with the methyltransferase inhibitor 5-Aza-2'-dC. 
We transduced four low-MASPIN expressing NSCLC cells lines 
with ATF-97, ATF-126 as well as controls and MASPIN mRNA 
levels were analyzed by real-time PCR 72 h post-transduction. 
As shown in figure 6 top, the combination of 5-Aza-2'-dC with 
ATF-97 upregulated MASPIN in a synergistic manner in all the 
four different cell lines analyzed; hence, the upregulation of the 
combination treatment was higher than the addition of the effects 
of the single treatments. In addition, for ATF-126 we observed 
synergistic interactions with the methyltransferase inhibi-
tor in some cell lines, including NCI-H157 (fig. 6, bottom). 
Moreover, in NCI-H157 cells the ATFs strongly synergized 
with 5-Aza-2'-dC to upregulate MASPIN expression as assessed 
by real-time quantification and western blot (fig. 6, bottom). 
In these cells, the combination treatment of the ATFs with 
Figure 4. aTF-126 inhibits metastatic dissemination in the NscLc 
NcI-h157 cell line stably expressing a luciferase reporter (Luc) in vivo. 
Top panel; in vivo Bioluminescence Imaging of control mice showing 
metastasis in the brain and spine at week six after receiving an intracar-
diac injection of 1 x 105 NcI-h157 cells transduced with control vector 
(empty retroviral vector). Bottom panel; Bioluminescence Imaging of 
aTF-126-injected mice twelve weeks after receiving an intracardiac 
injection of 1 x 105 NcI-h157 cells transduced with aTF-126 retroviral 
vector. Differences between the two groups were calculated using the 
Wilcoxon rank sum test with the level of significance of p ≤ 0.1.
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evidenced by the 100-fold increase in MASPIN transcript. These 
results are consistent with previous reports in breast cancer cell 
lines where the frequency of DNA promoter methylation strongly 
correlated with the degree of MASPIN mRNA expression.13 
The localized changes in DNA demethylation induced by the 
two ATFs in the close proximity of their binding sites suggest that 
enhanced transcription could be associated with increases acces-
sibility of the ATFs and Pol II complex.
The directionality of the demethylation pattern associated 
with ATF-126 and ATF-97 might be explained by the differential 
orientation of the activator domain of each ATF in complex with 
the target DNA. ATF-126 was designed to bind the “coding” 
DNA strand in the MASPIN promoter gene, thereby positioning 
the activator domain upstream the ATF binding site. In contrast, 
ATF-97 was designed to bind the complementary DNA strand, 
anchoring the activator domain downstream the ATF-binding 
site. It will be interesting to extend the mapping of the CpG 
dinucleotides in the MASPIN promoter further upstream and 
to address if indeed the ATFs alter chromatin accessibility patters 
by inducing localized relaxation of the chromatin, for example 
by DNAse footprint assays. It is also presently not known if the 
ATFs are able to locally remodel the chromatin by altering the 
binding to the DNA of endogenous proteins, such as histones 
and methyl-binding proteins.
Importantly, MASPIN reactivation upon ATF transduction was 
associated with site-specific promoter demethylation. Both ATF-97 
and ATF-126 significantly decreased the DNA methylation levels 
in the MASPIN proximal promoter region in the NCH-H157 cell 
line. ATF-126 decreased the frequency of DNA methylation by up 
to ~70%. Interestingly, the DNA sequences exhibiting decreased 
methylation frequencies were comprised in a 400 bp promoter 
region upstream the ATF-126 recognition site. In contrast, ATF-
97 reduced methylation frequencies by up to ~50% in a promoter 
region localized downstream its binding site. Even though these 
DNA methylation changes are relatively modest, they are associ-
ated with a strong degree of reactivation of the endogenous gene, as 
Figure 5. aTFs demethylate the MASPIN promoter in the NcI-h157 cell line. (a) Methylation status of the MASPIN promoter in untransduced NcI-h157 
cells. The X-axis represent the nucleotide position relative to the first methionine and Y-axis the percentage of methylation along the MASPIN proximal 
promoter region (495 to +134). The frequencies of 5-Methylcytosine were obtained by sodium bisulfite genomic sequencing of the MASPIN promoter33 
Known transcription factor binding sites were included (p53-binding sites as well as aTF-binding sites). Red nucleotides indicate the methylated 
cytosines in the aTF-binding sites. (B) schematic representation of aTF-126 and aTF-97 illustrating the positioning of the six zinc finger (ZF-97 and ZF-
126) DNa binding domains and the Vp64 effector domain (blue circles) in the promoter. (c) Methylation status of the MASPIN promoter in aTF-97- and 
aTF-126-transduced cells.
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similarly alter other epigenetic marks in the MASPIN promoter, 
such histone H3 lysine9 methylation, which has been previously 
associated with the silencing of MASPIN and other tumor sup-
pressors in breast cancer.51
Alternatively to a passive mechanism of demethylation, it 
is also possible that DNA demethylases recruited to the RNA 
Pol II complex would enzymatically demethylate the promoter 
in a more direct manner. However, regardless of the mechanism 
of demethylation, our results suggest that ATFs can be used to 
target DNA demethylation into specific promoters. Our future 
engineering of ATFs will include the linkage of specific DNA-
binding domains along with protein domains that actively 
demethylate DNA or histone substrates. The construction of 
sequence-specific ATFs could be used by investigators to address 
important questions such as the impact of demethylation in the 
generation and maintenance of other epigenetic marks, promoter 
accessibility and gene transcription.
The ATF-mediated reactivation of MASPIN in lung cancer 
cell lines resulted in complex functional outcomes, including 
induction of apoptosis, suppression of cell invasion and experi-
mental metastasis formation in nude mice. This is consistent with 
the role of MASPIN as a multifaceted tumor suppressor involved 
in many cellular processes. In breast and prostate cancers, upreg-
ulation of MASPIN is associated with induction of apoptosis52,54 
suppression of cell invasion,16,17 and suppression of angiogenesis.15 
downstream the ATF-binding sites, which will allow us to have 
a better understanding of the ATF’s demethylation potential. 
Nevertheless, in the best of our knowledge this is the first report 
of ATFs that is able to effectively demethylate their targeted pro-
moter resulting in a reactivation of an otherwise silenced gene.
The mechanism by which the ATFs DNA demethylate the 
MASPIN promoter remains elusive. Recent studies suggest that 
cross-talk occurs between different epigenetic processes, such as 
histone acetylation, histone and DNA methylation and nucleo-
some remodelers.46 Significantly, our results suggest that DNA 
demethylation and reactivation of the MASPIN promoter by 
ATFs require a VP64 activator domain properly anchored in the 
promoter by a specific DNA-binding domain. The VP64 effector 
domain a tetramer of VP16 (Herpes virus simplex VP16 activa-
tor domain) has been proposed to interact with MEDIATOR 
to recruit the RNA Pol II transcriptional complex.47 As integral 
members of this complex, histone acetyltransferases (HAT) 
as well as chromatin remodelers (SWN/SNF)48-50 are able to 
modify the combination of histone acetylation marks within 
the promoter.47 This allows a more open and accessible chroma-
tin conformation, resulting in enhanced gene transcription. In 
this regard, demethylation of the MASPIN promoter represents 
an indirect or passive mechanism consequential from recruit-
ment of the RNA Pol II complex into the MASPIN promoter. 
In future experiments it will be important to investigate if ATFs 
Figure 6. aTFs synergize with 5-aza-2'-dc to reactivate MASPIN in NscLc Low-MaspIN expressing cell lines. Non-transduced and transduced cells 
were treated with 5 μM of 5-aza-2'-dc for 48 h. MASPIN mRNa expression levels were measured by quantitative real-time pcR. MaspIN protein expres-
sion in NcI-h157 cells was determined by western blot. Experiments were run in triplicate and data represent the mean ± sD three independent ex-
periments (*p < 0.05, as determined by student’s t-test). Nch-a549, Nch-h226, Nch-h1703 and Nch-h157 are referred to as “cell line;” aTF-97, aTF-126 
and aTF-452, represent cells transduced with the corresponding aTFs.
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particles. Transfection was done using Lipofectamine according 
to the manufacture’s instructions (Invitrogen). The viral super-
natant was used to infect the host cell lines, and the infection 
efficiency was assessed by flow cytometry (FACSCalibur, BD 
Biosciences) using green fluorescent protein as a marker.
stable nci-h157-luc cells. The retroviral vector (pLNX-
Luc) and the envelope plasmid expressing the vesicular stoma-
titis virus envelope protein (pMDG.1) were cotransfected into 
293TGag-Pol cells to produce retroviral particles. The viral super-
natant was used to infect the NCI-H157 cells. After two days, 
cells were placed under selection with Geneticin at 800 μg/ml 
for two weeks. Single colonies were isolated, expanded and used 
for animal experiments.
real-time gene expression assays. Total RNA from 1 x 106 
non-transduced, ATF-transduced cells and control cells were 
extracted using the RNeasy extraction kit (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. For reverse 
transcription, 2.5 μg of total RNA was used to prepare 
cDNA using the High Capacity cDNA Archive Kit (Applied 
Biosystems). Quantification of MASPIN, E-CADHERIN and 
GAPDH (Human GAPDH Endogenous Control) transcript 
expression was measured by real-time PCR using hydrolytic 
probes (Taqman, Applied BioSystems). All PCR reactions were 
performed in triplicate and under PCR previously published con-
ditions39 using independently prepared biological samples. Fold 
increase in gene expression for each sample and experimental 
condition was calculated as 2Ct(control) - Ct(sample) ± SD. Differences 
between groups were analyzed using the Student’s t-test or 
ANOVA. Significance level was set-up at p < 0.05 (indicated as *) 
and p < 0.01 (indicated as **).
western blotting. The NSCLC cell lines were collected 
in RIPA buffer. Total protein was purified and the concentra-
tion measured by a Bio-Rad DC protein Assay Kit (Bio-Rad 
Laboratories). Equal amounts of protein were subjected to a 
10% SDS-PAGE gel (Bio-Rad) and subsequently transferred to 
a PVDF membrane (Amersham Biosciences) by electroblotting. 
The membrane was washed twice in 0.05% TBST for 10 min, 
and then blocked with 5% milk in TBST for 1 hour at room tem-
perature. The primary monoclonal antibody against MASPIN 
(anti-human MASPIN antibody, clone G167-70; Pharmingen 
International) was diluted 1:1,000 in 1% milk/TBST. The mem-
brane was incubated overnight at room temperature and washed 
as described above. The secondary antibody, anti-human Tubulin 
(Amersham Biosciences), was diluted 1:5,000 in 1% milk/TBST 
for 45 min. MASPIN and TUBULIN proteins were detected 
with ECL Plus (Amersham Biosciences).
in vitro invasion assay. The non-transformed immortalized 
bronchial epithelial cell line BEAS-2B and all the NSCLC cell 
lines were seeded in a 24-well matrigel-coated invasion cham-
bers (BD Biosciences). The lower chambers were filled with 
0.5 ml of RPMI-1640 medium containing 10% fetal bovine 
serum (FBS). Cells were starved overnight and 5 x 105 cells in 
0.5 ml serum-free medium were added to the upper chamber. 
Cells were incubated for 18 h at 37°C in a humidified incuba-
tor with 5% CO
2
. The non-invading cells that remained on 
the upper surface of the membranes were removed by scraping. 
ATFs that reactivated MASPIN in lung cancer cell lines induced 
approximately 40% apoptosis relative to control-transduced cells. 
In addition, when the same cells were treated with 5-Aza-2'-dC 
an increase on MASPIN expression and an additional 20% apop-
tosis was observed. More recently, MASPIN has been shown to 
physically associate with HDAC1 to inhibit histone acetylation.55 
As a putative HDAC inhibitor, MASPIN could bind and reac-
tivate multiple tumor suppressor genes that are found repressed 
by HDAC1, including E-CADHERIN. In NCI-H157 cells the 
E-CADHERIN promoter is found repressed by transcription fac-
tor SNAIL.55,57 Consistently, treatment of NCI-H157 cells with 
HDAC inhibitors, and/or transduction with MASPIN-specific 
ATFs, also lead to reactivation of E-CADHERIN mRNA levels 
up to 50-fold relative to controls. Our results show that only a 
percentage of the transfected spheroids reactivate E-CADHERIN 
and the morphology of these spheroids exhibited more epi-
thelial phenotypic features. It is possible that a percentage of 
ATF-transduced cells induced apoptosis as expected from the 
re-activation of tumor suppressive functions. The survival pop-
ulation could reactivate other tumor suppressor genes such as 
E-CADHERIN and E2F,58 and thereby these cells would exhibit 
a more differentiated phenotype.
Overall, our work suggests that ATFs designed to upregulate 
MASPIN have therapeutic potential to suppress apoptosis and 
metastatic dissemination in lung cancers. Thus, reactivation of 
MASPIN by ATFs offers a unique therapeutic strategy to target 
multiple steps in the neoplastic progression. However, in order to 
be applied in the clinic, the ATFs need to be specifically delivered 
in tumor cells. The delivery of ATFs into tumor and metastasis is 
presently a critical limitation for its use as therapeutic agents in a 
clinical setting. However, novel nanoparticle targeted systems are 
being developed, witch will enable the encapsulation of the ATF-
encoded DNA or the ATF’s polypeptide specifically into tumor 
cells.59 In addition, novel adenoviral delivery systems are also in 
development possessing tumor-cell tropism.60,61 ATFs made of 
three zinc finger modules designed to regulate the Vascular endo-
thelial growth factor (VEGF) gene are presently in clinical trials, 
outlining the potential of the ATFs as therapeutic agents.62
Materials and Methods
cell lines. The human bronchial epithelial cells (BEAS-2B; 
ATCC CRL#9609) were cultured in BEGM plus addi-
tives (BEGM Kit Catalog No. CC-3170, Lonza/Clonetics 
Corporation). The human lung cancer cell lines NCH-H1648, 
NCI-H211, NCH-H385, NCI-H460, NCI-A549, NCI-H226, 
NCI-H520, NCI-H157, NCI-H1703 and NCI-H661 were kindly 
provided by Dr. Robert Winn (University of Colorado Health 
Science Center). All the lung cancer cell lines were cultured in 
RPMI-1640 medium supplemented with 10% fetal bovine serum 
and grown at 37°C in a humidified 5% CO
2
 incubator.
atf retroviral transduction. ATF-126, ATF-97 and ATF-
452 were cloned into the retroviral vector pMX-IRES-GFP as 
described.33 Retroviral vectors and a plasmid expressing the 
vesicular stomatitis virus envelope protein (pMDG.1) were 
first cotransfected into 293TGag-Pol cells to produce retroviral 
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Genomic sequencing of the MASPIN promoter. The meth-
ylation status of 19 CpG dinucleotides within the MASPIN 
gene promoter region was examined in bisulfite-modified DNA 
as described.12 Genomic DNA was isolated using the DNeasy 
Tissue Kit (Qiagen) and 1.5 μg was modified using EZ DNA 
Methylation-Gold kit (Zymo Research). Samples were then puri-
fied using Wizard DNA purification resin (Promega), treated 
with NaOH, precipitated with ethanol and resuspended in water. 
The MASPIN gene promoter was amplified from bisulfite-mod-
ified DNA by two rounds of PCR using nested primers specific 
to the bisulfite-modified sequence of the MASPIN gene as previ-
ously described.13,39 The resulting PCR products were cloned into 
a TA cloning vector according to the manufacturer’s instructions 
(Invitrogen). Ten positive recombinants were isolated, sequenced 
and the methylation status of individual CpG dinucleotides 
was determined by comparison of the sequence obtained with 
the known MASPIN promoter sequence.10 To obtain a percent-
age methylation value for each site, we divided the number 
of methylated CpGs at a specific site by the number of clones 
analyzed.
assay of spontaneous metastasis. Female SCID mice (age 
four weeks) were purchased from Taconic Farms, and housed 
under pathogen-free conditions. Each experiment group included 
five animals. Animals were injected with 1 x 105 NCI-H157-Luc 
cells transduced with ATF-126 and control vector (pMX-IRES-
GFP empty retroviral vector) in 100 μl sterile PBS into the left 
ventricle of the heart by nonsurgical procedures. Bioluminescent 
imaging was performed with a highly sensitive, cooled CCD 
camera mounted in a light-tight specimen box (IVISTM, 
Xenogen). The signal quantification was controlled with the 
analysis software Living Image® (Xenogen). For in vivo imag-
ing, animals were administered with the substrate D-luciferin by 
intraperitoneal injection at 150 mg/kg in DPBS and anesthetized 
(1–3% isoflurane). Animals were imaged from both dorsal and 
ventral views about 10 min after intraperitoneal injection of 
D-luciferin. Assessment of metastasis was monitored in vivo once 
a week for up to 12 weeks. Regions of interest (ROI) from dis-
played images were identified around the tumor sites. The bio-
luminescent signal was quantified as total photons per second 
(photons/s) by measuring the amount of highlighted pixels in 
each ROI with the aid of the Living Image® software (Xenogen). 
The total photons/s in ROI in each mouse were used to evaluate 
the differences between the two groups using the Wilcoxon rank 
sum test with the level of significance of p ≤ 0.1.
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The invasive cells attached to the lower surface of the membranes 
were fixed in methanol and stained with Hematoxylin/Eosin 
(Diff Quick stain Kit, IMEB INC.). The average number of 
invasive cells was counted under a microscope from four different 
fields of view from each well and a total number of three wells. 
Each experiment was performed three times. Differences between 
groups were analyzed by the Student’s t-test. Significance level 
was set-up at p < 0.05 (indicated as *) and p < 0.01 (indicated 
as **).
immunofluorescence assay. Lung cell lines were seeded in 
fibronectin-coated slides (5 x 104 cells) and grown for 24 h. Cells 
were washed with PBS (phosphate buffered saline pH 8.0) and 
fixed in paraformaldehyde for 20 min. Cells were washed and 
permeabilized with 0.5% Triton-X100 in PBS followed by block-
ing with 5% BSA for 2 h. These cells were then incubated with 
primary antibody (anti-MASPIN, BD Pharmingen) at 4°C over-
night. Expression of MASPIN was determined by FITC labeled 
secondary antibody (Invitrogen).
Quantification of apoptotic cells. Quantification of apoptosis 
was determined by flow cytometry using the Annexin-V staining 
kit (BD Biosciences) following the instructions of the manufac-
turer. Apoptosis was measured 96 h post-transduction. A positive 
control was induced with 10 μM camptothecin (Sigma) for 24 h 
prior analysis to calibrate the flow cytometry settings. Apoptosis 
was measured by flow cytometry using a FACS Calibur cytom-
eter and CellQuest software (BD Biosciences). The percentage of 
apoptotic cells was calculated by comparing each sample with the 
non-transduced sample. Differences between groups were ana-
lyzed the Student’s t-test. Significance level was set-up at p < 0.05 
(indicated as *) and p < 0.01 (indicated as **).
colony formation assay. Non-transduced cells, control trans-
duced cells and cells transduced with ATFs, were seeded in trip-
licate at a density of 3 x 103 cells per well in a six-well plate. The 
wells were pre-coated with 0.6% agarose in growth medium, and 
then coated with an additional layer containing 0.3% agarose 
in RPMI-1640 medium supplemented with 10% fetal bovine 
serum. After incubation at 37°C for three weeks, the cells were 
stained with 0.005% crystal violet. Colonies, which were defined 
as groups of a minimum of 50 cells, were counted using phase 
contrast microscopy. Colony formation was assessed in three 
independent experiments. Differences between groups were ana-
lyzed with the Student’s t-test. Significance level was set-up at 
p < 0.05 (indicated as *) and p < 0.01 (indicated as **).
three-dimensional cell culture. Cells were grown in 3D 
basement membrane cultures as described49 with the following 
modifications. Growth factor-reduced Matrigel (BD Biosciences) 
was combined in a 1:1 ratio with complete serum medium 
(RPMI 1640 medium containing 10% fetal bovine serum). 100 
μl were added to each well of an eight-well glass slide chamber 
and allowed to solidify for 2 h in at 37°C incubator. Cells were 
trypsinized, counted and diluted to 25,000 cells/ml. The cell sus-
pension was combined in a 1:1 ratio with a 10% Matrigel solu-
tion and 200 μl of this mixture was added to each well for a 
final concentration of 5,000 cells/well in 5% Matrigel. Cells were 
fed with complete serum medium containing 5% Matrigel every 
three days for a period of three weeks.
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